Th is review present s bri efly th e resu lt s of a number of stu dies conducted In healt hy vo lun teers, designed to i nvestigate the pharmac okinetics of famc lclov i r. the oral form of the anti viral compound , pen ciclovir. These studies have show n th at famci clovi r is absorbed rap idly and extensive ly foll owing oral administration. Extens ive pre-sy stemi c metabolism of famcicl ovi r occ urs si nce co mpo und-related material in plasm a co nsists almost enti rely of deacetylaled and oxidize d metabol ites. little or no pare nt compound is detect ed In plasma or urine. The ma jo r metabolite of tamctctovtr is pencicl ovir. Maximum plasma co nce ntrations of pen cic tc vtr are ach ieved rap idl y foll ow ing ora l administration of ta mctcr cvrr, and total sys temic avail abilit y of penciclovi r is high (77%). Pharmacokl netl c paramete rs for penci clovir are lin ear over th e famcl clovi r oral dos e r ang e 125-750mg and the pencl clovl r Intravenous dose rang e 1O-20 mg kg-1 • The distribution of pencicl ovir afte r intravenous adminis tration Is consi ste nt wit h locali zation ou t of plas ma and Into ti ssues. Penc iclo vlr Is eli mi nated rapidl y and al most unchanged by net active tu bul ar secretion and glo merular filtrati on in th e kidn eys. The terminal pha se eli mi nation halfl ife of th e compound In healthy SUbjects is approximately 2 h. A study in health y elde rly male subje cts indi cated no cli nica lly signif icant effects of age on th e ph armacokinetics of penctct cvtr following oral f ameletovir adminis tration. Food appears to slo w the rate of ava ila bilit y of penclc lcvlr fr om oral tam crctcvr r, but has no effe cts on the ex tent of avai lability of p enclclovir. These data Ind icate that famciclovi r possesses exce lle nt pharm acokineti c prop erti es fo r t he provi sion of clinica lly u sef ul co ncen trations o f th e antiviral agen t penclclovir in the oral treatment o f herpesviral in fection s.
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Introducti on
Famciclovir is the diacetyl6-deoxy analogue of the active antiviral aqem pencclovir and is under development for the oral treatment of varicella-zoster virus (VZV) and herpes simplex virus types 1 and 2 (HSV-1, HSV-2) infections. Penciclovir inhibits laboratory strains of HSV-t , HSV·2, VZV, and Epstein-Barr virus (EBV) (Boyd et et.. 1987) . Penciclovir is highly selective against herpesviruses because it is only phosphorylated in herpesvirus-infected cells (Vere Hodge and Perkins, 1989; Earnshaw et al., 1992) . Famciclovir was selected for development because it displayed good stability in human duodenal contents, thus allowing absorption, yet was converted to penciclovir by intestinal and liver tissues (vere Hodge et aI., 1989 ) ,
The metabolism of lamcidovir In tissue extracts and rats has been proposed to proceed via the metabolic sequence shown in Fig. 1 (Vere Hodge et al., 1989) . The major pathway is via di-oeacetyletion to BAL 42359, followed by oxidation at the 6-position of the purine ring to form penciclovir.
In this review, the results 01 a number of studies designed to investigate the pbarmacckinetcs of famcicio vtr in man will be discussed. The primary focus will be on the pharmacokinetics of penciclovir followinq oral administration of remctciovir. but reference is also made to the pharmacokinetics of an intravenous dose of penciclovir . All lhese studies were conducted in healthy male subjects and represent single and repeat dose administration of Iamcictovir, dose proportionality, and food interaction studies. Results of some more recent work, mctuding absolute bioavailability studies and a study in patients with shingles, are mentioned briefly.
Bri ef summa ry of meth od s A general outline 01 the studies is summarized below. Between six and 20 subjects were included in each study which was conducted in accordance with the declaration of Helsinki (revised 1975 . Tokyo , amended 1983 . Venice, and 1989 . The ororocortor each stUdy was reviewed and approved by an independent Ethics Committee. Famcidovir was administered as a capsule or tablet at doses over the range 125-1{)()() mg.
In general, serial blood and urine samples were collected preoose and at frequent intervals up to 24 h alt er dosing. Blood was collected into tubes containing fluo- Hodge et ai" 1989 , Alllimi crob Ag ents ChemOlher33 , 1765 -1773 ride/EOTA or EOTA and plasma generated by standard centrifugation techniques. Plasma and urine samples were stored at approximately -20°C or colder prior to analysis.
Plasma and urine concentrations of tamcciow and its metabolites were measured using reversed-phase hiQh perlormance liquid chromatography (HPLC) with UV detection. The specific analytical method used depended upon the study objectives and measured famciclovir and its metabolites (Winton et al., 1990) , penciclovir, and its immediate precursor, SRL 42359 (McMeekin et et., 1992) or penclcfovir alone (Fowles and Pierce, 1989) . All these methods have been shown to be specific, precise, and reproducible with between-and within-day coellicents of variation 01 less than 20%. Penciclovir plasma concentration-time data were analysed by standard model-independent pharmacokinetic techniques . The area under the plasma concentration-time curve (AUG) was calculated from time 0 to infinity.
Studies in healthy young individu als

Pharmacokinetics of differen t oral doses
Orally administered famciclovir is absorbed extensively and converted rapidly to the active antiviral metabolite. penctclovlr . Absorbed famciclovir undergoes extensive oresystemrc metabolism since little or no unchanged ramcctovtr is detected in plasma, even following repeat dose administration at 1000 mg (Winton et al., 1990) . Compound-related material in plasma and urine consists essentially of penciclovir and, to a lesser extent, its 6deoxy precursor SRL 42359 at all lime points invesftcated. Hydrolysis of famciclovir is believed to occur primarily in blood and possibly intestinal tissue and liver, with oxidation of SRl 42359 to penciclovir occurring in liver (Vere Hodge at al., 1989) .
The plasma pharmacokinetics of penciclovir following oral famciclovir administration have been investigated in a number or studies in healthy male volunteers. Figure 2 presents mean plasma concentration-time profiles for oenccrovn and SRl 42359 following single oral administration of Iamciclcvir at a dose of 500 mg to 20 healthy male subjects (Prall et al., 1993) . Following oral administration, famciclovir is absorbed rapidly and maximum plasma concentrations of penciclovir are attained at a median lime of 0.75h (range O.5-1.0h). Thereafter, plasma concentrations of penciclovir decline generally biexponentially with time and are at. or approaching. the level of detection (O.2llg mr') by 8h post-dose ( Fig. 2) . Plasma concentrations of BRl 42359 are typically at least three-told less lhan plasma concentrations of penciclovtr and detectable only for a relatively limited period of lime following oral dosing of famciclovir.
Penciclovir is the major drug-related component detected in both the plasma and urine. Approximately , 19 93 .) Pharmacokinetics of famciclovir in man 49 ted in a randomized, single-blind, placeb o-con trolled study in 20 healthy male volu nteers (Pratt et al., 1993) , Pencictovir pla sma concentration-time data for one subject, typi cal of all the other subjects in this study , are presented in Fig . 3 . Pharmacokinetic data for penctclovir are summarized in Table 1 . In order to assess dose linear ity , the area und er the plasma concentratio n-time curve (AUC) and max imum pla sma concentration (C ma . ) values were dos e-normalized and expressed as geometric mean ratios relative to the Iam cclovir 250 mg refe rence dose. The geometri c mean ratio s of the other pha rmacokin etic para meter s we re estimated in order to ass ess whether these parameters remained consta nt across the dose range . Dose proportionality was concluded if the 90% confidence intervals for the ratio of the geometric mean s of the pharmacokinetic param eters for each dose leve l relative to the 250 mg dose level were complete ly contained within the range (0.8, 1.25). Using these criteria, the pharmacokinetics of pen ciclovir were sho wn to be 65% of the administered dose of tamccrovtr is excreted in urine as penclcsov'r (60"/,,) and SRL 42359 (5%) . Hence, absorption of compound-related material following oral administration of lamciclovir is high. Furthermore, the bioava ilability (F) of penciclovir from oral famci clovi r, as evidenced by urina ry recovery of penciciovir, is good (minimum of 60% , or F = 0.6). This has been subsequently confi rmed in a more recent study designed spe cifically to investigate the systemic bioavailability of penciclovir from oral famciclo vir (500 mg) relative to an intravenous dose of penci clovir. The absolute bioavailability of pencictovir in this study , cond ucted in 12 healthy male subjects, was 0. 77 (95% confidence inte rval 72% 83 %) , indicating a relatively smal l degree of variability for this drug (S .K. Pra tt, A.J. Fairless , M.A. Pue , R.S. Hucker, S8, We lwyn, UK ; H. Sourgens, H. Coll ie , FOCUS , Clinical Drug Development, Neuss , Ge rmany ; persona l com munications).
The potential dose dependency in penciclovir pharmacokinetics follow ing single oral administration of famciclovir at doses of 125 , 250, 500, or 750 mg has bee n stud-õ 
Pharmacokinetics of intravenous penciclov;r
In order to examine the disposition of penciclovir directly, the pharmacokinetics 01the compound have been investi · gated lollowing single intravenou s infusion of penciclovir to three groups , each consis ting of five healthy male subjects , at doses of 10, 15, or 20mgkg-' (Fowles et al., 1992a) . Mean pencid ovir plasma concen tration-time profiles following cons tant rate intravenous infusion over 1 h are pres ented in Fig. 5 . At each of the dose levels investigated, the majority of the dose , approximately 70%, was excreted unchanged in the urine (Table 2) . More than two-thirds of this was recov ered in the first 4 h after the start 01the infusion, indicating rapid elimination. As was the case following oral administrali on 01famcidovir, mean renal clearance values for penciclovi r (27. 1-29.8 I h-') exceeded normal glomerular filtration and accou nted for more than 70% of the total plasma clearance of the compound. Although . by implication, these data suggest that approximately 30 % of the dose 01penciclovir was cleared by non -renal mechanism(s), no drug -related material other than penciclovir was detected in plasma or urine during this study. Indeed , more recent studies have demonstrat ed quantitative recovery of penciclovir in urine following administration 01 radiolabelled compound to healthy volunte ers, confirming that penciclovir underg oes very little metaboli sm in man and is cleared almost entirely by the renal route. The mean apparent volume 01distribution (V~) of pencrclovir following intravenou s admi nistration was estimated as app roximately l OC H (Table 2) , indica ting that peoct-cIovir distributes extensively into tissues. (Table 1) . These values exceed glomerular filtration rate in man (approximately 7 I h-I ; Aemingtons Pharmaceutica l Sciences , 1985), and approach renal plasma flow (36-42 I h-1 ; Aemingtons Pharmaceutical Sciences, 1985) . Since the blood-to-plasma ratio of pencciow is approximately 1 and serum protein binding is low «20%), these data indicate that both net active tubular secretion and passive filtration are involved in the renal elimination of pencid ovir, and suggest that the clearance of penctcreve may be dependent upon renal blood flow.
A recentty completed study has shown that the pharmacokinetics of penciclovir following single and repea t (every 8h) oral administration 01 tamcicovir to patient s with shingles are essentially identical to those in agematched health y subjects. These results indicate that pharmacokinetic data for penciclovir in healthy volunteers are predictive of the disposition of ramcicrovn in herpeszoster patients and, lor varicella -zoster at least , viral disease does not affect the pharmacokinehcs of famclclovir The effect of age on the pharmacokinetics 01 penciclovir following oral administration of famciclovir was investigated in an open study in which 18 healthy elderly male volunteers (age range 65-79 years) received a single oral dose 01tamciclovir (750 mg) (Fowles et at., 1992b) . Penocrovu and its precursor, BRL 42359, were found to be the major metabolites of tamctclovir detected at quantifiable concentrations in plasma and urine of elderly subjects. As in healthy younger individuals, ramcictovrr was absorbed rapidly in the elderly, with C ITllI X of pencclovir being obtained at a median lime of 0.9 h post-dose ( Fig.  6) . A summary of the pharmacokinetic parameter estimates lor penciclo vir in this group of subjects is presented in Table 3 . As in healthy young subjects, the renal pathway was the principal route of elimination in elderly subjects, with approximately 700 .4 01 the dose recovered as penciclovir and BAL 42359 in urine collected up to 24 h post-dose. The mean renal clearance value lor pencciovir, when adjusted lor body weight, was slightly tower (approximately 17%) than that reporled for healthy young subjects. As a consequence of this small reduction in renal elimination of the compound , the mean dose-nor malized AUC value for penclclovtr was slightly higher. and the mean t l /2 slightly longer, in elderly subjects compared The apparent terminal phase elimination half-life (t Il2 ) for pencictow following intravenous administration is approximat ely 2 h (Table 2) . This value is similar to that obtained for penciclovir following oral administratio n of tamciclovir (Table 1) . As may be expected from this relatively shorl half-life and time-independen t pharmacoki netics. no significant accumulation of penctclovir is evident follow ing repeal oral administration of tamcciovrr given once every 8h to healthy volunteers (Winton et al., 1990 ) .
Mean AUC and C"... values for penciclovir increased linearly wilh increasing dose level over the intrave nous range l o-20mg kg-1 (Table 2) . Furtnerrrcrethere we re no significant differences between Ihe doses for any of the pharmacokinetic parameters calculated for penclciovn (total clearance. volume of distribution, renal clea rance or t ll : } The se data are consistent with results observed following oral administration of tamciclcvir and indicate that no clinically relevant change s in the abso rption and metabolism of famciclovir or disposition and elimination of penciclovir are evident over the therapeuti c dose range. with healthy young subjects. However, all parameter estimates in the healthy elderly subjects in this study were within the range of values reported in healthy young subjects following administration of the same dose (750 mg; Table3 cf. Table 1) .
Penciclovir is predominate ly eliminated by the kidneys in both elderly and young volunteers. Creatinine clearances in the elderly subject s in this study were, with the excepti on of one subject, 5O-105 ml min-I , i.e. at the lower end of the range for normal renal function (76-177mlmin-'). These data suggest that the slightly lower renal clearance 01penciclovir following oral administration of famciclo vir in the healthy elderly subjects in this study is consistent with the lower renal function in this population compared with health y young subjects.
Although there is some evidence of slightly higher AUC values in healthy elderly SUbjects compared with young , systemic exposure to penciclovlr remained within the ranges of values reported for healthy young volunteers. Furtherm ore, t l12 estima tes for penciclovir in the elderly population, as in the young, are short relative to the dosing interval 018 h. Thus, significant accumulation of penclclovir in elderly patients with unimpaired renal function is not anticipated.
Famciclo vir-food i nt eractions
The effect of food upon the bioavailability and pharmacokinetics of pencciow following oral administration of famciclovir has been investigated in two separate studies. In the first study, each of 12 healthy male subjects received tamcrciovtr (250 ur 500 rug) by capsule in either the fed or fasted state ue. 30 min after or 2 h before a standard cooked breakfast) in a 4-way crossov er design . In a second study, each of 18 healthy male subjects received a single oral dose 01tarnciclo vir (500 mg) as a tablet either 2 h before or 2 h after a standard cooked break fast, in a 2-way crossover design (Fowles et a/., 1991) .
No significant differences (at the 5% level) were found in dose-normalized AUC, elimination half-life, urinary reco very, or renal clearance 01 penciclovir following oral administration of tamctclovir (250 or 500 mg) 2 h prior to, or 30min following, food (Table 4) . However, at both dose levels , C max of penciclovir was significan tly (P c 0.005) lower, and the time to maximum plasma concent ration (t,....x) significantly (P -c 0.005) longer, in the fed compared with the fasted state. Mean C"",x values following tarrciciow (250 and 5OOmg) 30 min after food were 1.01 and 1.89jJgml-1 , respectively, compared with 1.90 and 3A6jJg ml-1 when administered to fasted individuals (Table 4 ). In accordance with the studies described above, both C""", and AUC increased in a linear mann er between dose levels, irrespective of the fed or fasted state 01 the subjects . Neither urinary recovery nor renal clearance 01oeocciovir was altered between dose levels, or with led or fasted status of the subjects. Mean elimination halt-hie and renal clearance values of penciclovir in this study accorded closely with mean values observe d followi ng intravenou s administration of penci clovir itself (cl. Table 2 ). Figure 7 presen ts mean penciclovir plasma concentration-time profiles following oral administration of tamerclovir (500mg) as a tablet 2h before , or 2h after food. Mean ratios (fed:las ted) for AUG, elimination half-life, urinary recovery, and renal clearance for penciclovir were close to unity with 90% conl idence interv als for these ratios within the range (0.8, 1.2), indicating equivalence between the treatments with respect 10 these parameters (Table 5 ). However, equivalence between treatments could not be claimed for C max ' as the 90% confidence interval lor this parameter overlapped (he lower limit of the range (0.8, 1.2). Furthermo re, I" ... . was delaYAn hya median 01 1.1 h when famciclovir was admin istered 2 h after food.
The results of these studies indicate that administration of tamec lovlr either 30 min or 2 h after food does net lead to any significant change in the extent of availability or elimination characteristics of peociclovir. The presence of food in the gastrointeshnaltract does appear to slow the rate of absorption of tamciclovir and/or its conversion to penciclovir for bolh capsule and tablet lormulations, with T able 4. Me3l1 (:t SO) Of media n (t range ) pha rmaookinetic para meters far pe rlCiclovir follo wing ora l famcidoVir capsu le 250 or 500 mg 30 min all er f led') or 2 h before (1asled") 8 standard cooked break fast la 12 healthy male -.-' 2 50 mg 500 mg Pharmacok'llehc pa ramet er (unIts) '''' , 1991 .) an effect on the tablel still apparent up to 2 h afte r food. However, as is discussed below , the size of these changes is not considered to be of clinical significance.
In contrast. the absorption of ora lly administered acyclovir in man is slow , variabl e and incomplete (de Miranda and Good, 1992) . Wh ilst the minimum bioavailability of penciclovi r from oral famciclovir, estimated by urinary recovery dat a, is high (> 60%) and dose-independent , the oral bioavailabitity of acyclovir from capsules, esti mated similarly, is low, rangin g from 10 to 20% in patients (Strauss et et.. 1982 ; de Miranda and Blum, 1983) . The absolute bioavailability of acyclovir estimated followi ng singl e oral administration at a oose of 200 mg in healthy volunt eers in a randomized crossover study was 20% (de Miranda and Blum, 1983 ; Brigden and Whiteman , 1985) .
System ic availability of acyclovir appears to decrease with increas ing dose. Bridgen et a/. (1980 ) reported that the percentage of the dos e recovered in urine after single oral administration of acyclovir decreased from 13% following a dos e of 100 mg to 6% following a do se of 600 mg. At 800 mg, the percentage of the dose of acyclovir recovered in urine at steady-state was app roximately 10% (Selby et a/., 1984) . In a repeat -dose study in immunocompromised patients with herpes simplex or varicella -zoster infecti ons , mean peak steady-state plasma concen trations of acyclovir following doses of 200 , 400, or 600mg eve ry 4h were 0.5,1.2, and 1.3~g m l -l, respectively ; i.e. less than dose-proportional (de Miranda and Blum , 1983) . In contrast, AUG values during the dose interval at steady state incre ased linearly with dose and the percent urinary recovery of acyclovir was unchanged for the patients receiving the 200, 400 , and 600 mg dosing regimens, suggesting dose-proportional oral pharmacokinetics. However, other data (Rogers and Fowle , 1983) suggesf dose-dep endent pharmacokinetics for acyclovir followi ng single oral doses of 200 , 400 , and 800 mg in healthy volunteers. Acyclov ir exhibits dose-independent linear pharmacokinetics following intravenous administ ration over the dose range 0.5-5 mg kg-1 (de Miranda et al., 1979) .
Cap acity-limited st sorotton of acyclov ir has been suggest ed from a study in healthy volunteers which indicat ed that syst emic avai labili ty (AUC) of acyclovir was significantly greater following administratio n of a solution (either ... The studies described demonstrate thai famciclovir is absorbed rapidly and extensively following oral administration to man . Extensive presystemlc metabolism of tarnciciovir occurs since absorbed malerial consists almost entirely of deacelylaled and oxidized metabolites. Little or no parent compound is detected in plasma and urine. The majo r metabolite of tamciclovir is the active antiviral compound pencictovir. Maximum plasma concentratio ns of penctclovir are achieved rapidly followi ng oral administration of famciclovir, and tota l systemic availability of pendclovir is high (77%). Pharmacokinelic parameters for penciclovir are linear over the famciclcvlr oral dose range 125-750 mg and over the penclclovir intravenous range of 10-20 mg kg-I.
Pharmacokinelic
Two boucs before Two hours after Ral io 01means' para meter (Units) foo d ('lasted') tooc f led') fedifasled 90% Cl by intraduodenal infusio n or by sipping 01 the solution) than after administration 01 a tablet (Lew is et al., 1986) . The higher absorption 01 acyclovir following administration 0 1the solution ov er an extended time pe riod wa s conside red to be due to increased contact tim e 01 the solution with abso rptive area s of the intestine. In an earlier stLKIy, m ean systemic exposure to acyclovir was almost three times high er whe n a 600 mg dose was admi nistered in divided doses at 4 h interv als to healthy subjects compared with a single 600 mg dose (Bridgen et al., 1980) . Food has been shown to de cre ase both the rate (C rna x ) and ex ten t (AUG) of systemic av ailability of acyclovir 101lowi ng oral administra tion (Wilson et al., 198 7) . These data suggest that the bioa vailability of acyclovir, whilst relative ly low in the lasted state, is further compromised by administration 01the compound with food . In contrast, th e presence of food in the gastrointestinal tract has no effect on the extent of sys temic availability (bioava ilab ility) 01 penciclovir from ora l tamcic iovir . However, lood do es appear to slow the rate of availability of penciclovir. Des pite this decrease in the rate of availabi lity , maximum plasma co nce ntrations 01pe nc iclovir following tamceiovir (250 mg ) with food still exceed co ncentrations require d to inhibit VZV DNA synt hesis (E C so value s of c.t upmr' . Bacon and Schina zi, 1993) . Mech ani stic studies with HSV-inlected cell lines have shown that the rate of formation of penciclovir-tnphosphate is pr opo rtion al to the concentration of penciclovir outs ide the cell, at least over the conc entration range 0.25-2.5119mr l . Provi ded plasma concentrations clea rly exceed lC so values, it has been argued (Ve re Hodge, 1993) that AUC sho uld be con sidered a mor e impo rta nt parameter tha n G rna x for pe nclciovir antiviral activity . Th erefore, the decrease d rate of availability of pe nc iclovi r from famciclovi r in the presence of food is un like ly to be 01an y clinical significance for the therapeutic utility of lamciclo vir in man.
Penciclovir is rapidly and almost entirely eliminated by the kid ney . Rena l clearance of pencictovtr exceeds creatinine clearance in hum an s, indi cating the invo lve me nt of both net tubu lar secretion and glom erula r liltra tion in elimination 01 the compound. These findings are similar to da ta reported for acyclov ir (de Mi rand a and Good, 1992). Slightly slowe r elimi nat ion of pe nci clov ir has be en noted in healthy elderl y SUbjects with renalfunction at the lower end of th e norm al rang e, but the extent or the differences be tween this popula tion and healthy yo ung SUbjec ts does not warran t dose adjus tm ent in the elderly.
In summary, the studies discussed in this review demonstrate that tamciclc vir , the diace tyl 6-deox y derivative of the antiherpesv irus ag ent penciclovir, is rap idly and well absorbed following oral administration in man . Maximum plasma conce ntrat ions 01 penctdovir are achieved rapidly and total systemic availability of penciclovir is high. Bioavailability of penciclovir is unaffected by food and the pharmacokinetics of the compound are linear ov er the fam ciclovir oral dose range 125-750 m g. Th ese data indi ca te that famciclovir possesses excellent pharmacokinetic prop erties for the prov ision 01clinically useful concentrations of the antiviral age nt penci clo vir in Ihe oral treatme nt of herpesviral infections.
